# A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)

> **NCT02349425** · PHASE2 · COMPLETED · sponsor: **Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 59 (actual)

## Conditions studied

- Refractory Chronic Cough

## Interventions

- **DRUG:** Gefapixant
- **DRUG:** Placebo (for gefapixant)

## Key facts

- **NCT ID:** NCT02349425
- **Lead sponsor:** Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-09
- **Primary completion:** 2016-02-01
- **Final completion:** 2016-02-09
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2020-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02349425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02349425, "A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02349425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*